Triflusal vs Aspirin for the Prevention of Infarction: Randomized Stroke Study "TAPIRSS"

Completed

Phase 3 Results

Trial Description

To compare triflusal and aspirin in the secondary prevention of ischemic stroke.

Interventions

  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Triflusal (Disgren)Drug
    Other Names: DisgrenĀ®
    Intervention Desc: Antiplatelet agent structurally related to aspirin

Trial Design

Randomized, double-blind, multicenter pilot trial of 431 patients.

Patient Involvement

Patients were randomized to receive aspirin (325 mg/day) or trifusal (600 mg/day) for a median of 586 days.

Outcomes

Type Measure Time Frame Safety Issue
Primary Vascular death, non-fatal stroke, non-fatal MI, or major bleeding.
Secondary Non-vascular death, non-severe hemorrhage, systemic thromboembolism.

Sponsors

J. Uriach & Cia, S.A.